Crohn's DiseaseNCT03256240
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
A study testing side-to-side functional end anastomosis and Kono-S analstomosis in people with Crohn's Disease, run by Weill Medical College of Cornell University at 15 sites in 6 countries.
Trial summary
This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Crohn's Disease
- What is being tested?
- side-to-side functional end anastomosis and Kono-S analstomosis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 15 sitesin 6 countries
- Study dates
- 12 Mar 2014to 31 Dec 2036
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with Crohn's ileitis or ileocolitis requiring initial surgical resection.
- Age of 18 years and older, male and female
- All Phenotypes of Crohn's diisease will be included: nonpenetrating (B1), stricturing (B2), and penetrating (fistulating) (B3), according to the Vienna classification
- The patients can be on any medications coming into surgery, including prior anti- tumor necrosis factor(TNF) therapy.
Who cannot join
- Patients under 18 years of age
- Patients with recurrent Crohn's
- Pregnant patients
- Patients with more than one non-contiguous site of active disease, thus requiring multiple resections or additional bowel sparing procedures at the time of surgery.
- Patients with Crohn's disease extending to the cecum and ascending colon
- Patients who will need preventive postoperative medical treatment
- Patients that need change of surgical procedure as per the surgeon at the time of the intraoperative abdominal evaluation.
Trial locations and contacts
15 sites in 6 countries. Contact the study team or a site near you to ask about taking part.
15 sites in 6 countries
United States6 sites, 1 recruiting
- Terminated
Massachusetts General Hospital
Boston, Massachusetts, 02114
- Terminated
Baylor Scott & White Research Institute
Dallas, Texas, 75204
- Terminated
Baylor College of Medicine
Houston, Texas, 77030
- Recruiting
Weill Cornell Medical College
New York, New York, 10065
Koiana Ivanova Trencheva, BSN,M.S., 646-962-2342, kivanova@med.cornell.edu
- Terminated
University of Oklahoma
Oklahoma City, Oklahoma, 73112
- Terminated
University of Washington Medical Center
Seattle, Washington, 98195
Germany3 sites, 3 recruiting
- Recruiting
Charité Campus Benjamin Franklin
Berlin, 12203
Swantje Malinka, MD, swantje.malinka@charite.de
Richard Mertens, MD, richard.mertens@charite.de
- Recruiting
Theresien Hospital and St. Hedwigs Clinic gGmbH
Mannheim, 68165
Peter Kienle,, MD, 0049621 / 424-4252,, p.kienle@theresienkrankenhaus.de
Kirsten Staiger, (0621) 424-5809, K.Staiger@theresienkrankenhaus.de
- Recruiting
Universitätsklinik Würzburg
Würzburg, Wurzburg, D-97080
Sven Flemming, MD, Flemming_S@ukw.de
Sven Flemming, MD
Italy3 sites, 3 recruiting
- Recruiting
Azienda Ospedaliero-Universitaria Careggi
Florence, Florence, 50134
Stefano Scaringi, MD, stefano.scaringi@unifi.it
Stefano Scaringi, MD
- Recruiting
Policlinico University Hospital
Naples
Gaetano Luglio, MD, gaetano.luglio@unina.it
Francesca Tropeano, fpt.tropeano@gmail.com
- Recruiting
Humanitas University Hospital
Rozzano, Milan, 20089
Annalisa Maroli, PhD, 39 02 82247776, annalisa.maroli@cancercenter.humanitas.it
Antonino Spinelli, MD, 39 02 82247776, antonino.spinelli@hunimed.eu
Belgium1 site, 1 recruiting
- Recruiting
University Clinics Gasthuisberg Herestraat
Leuven, 3000
Isabelle Terrasson, +32 16 34 08 37, isabelle.terrasson@uzleuven.be
Andre D' Hoore, MD, +32 16 34 08 37, andre.dhoore@uzleuven.be
Finland1 site
- Terminated
Helsinki University Hospital
Helsinki, Helsinki, 00029
Spain1 site
- Terminated
Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, 08035
About this study
Official title: Prospective Randomized Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis in the Prevention of Post-operative Recurrence of Crohn's Disease
This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
Read the detailed description
Study Aim:
- The primary aim of this study is to compare the postoperative recurrence of CD using the modified Rutgeerts score at 3-6 months between the novel Kono-S anastomosis (Group1) and side-to-side functional end anastomosis (Group2) and surgical recurrence rate at 60 and 120 months between the groups. Evaluate histologic features in surgical specimen collected at the index surgery as predictors for endoscopic, clinical, and surgical recurrence after ileocecal resection for CD. To evaluate the histological mucosal healing at 60 months between the novel Kono-S anastomosis (Group1) and side-to-side functional end anastomosis (Group2) using Global Histology Activity Score and The Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] score.
- The secondary aim is to evaluate the postoperative endoscopic recurrence of CD using the modified Rutgeerts score at 12-18, 60 and 120 months between the groups; time to surgical recurrence between Group1 and Group2 measured in months from the index surgery; yearly Crohn's disease surgical therapy impact using the Work Productivity and Activity Impairment (WPAI) questionnaire; yearly Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire; to evaluate before surgery, and yearly after the surgery up 60 months the patient perception of illness measured by The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score between the groups, to evaluate disease activity yearly using Harvey-Bradshaw Index, and monitor medication therapy, anastomotic strictures, readmission rates, and mortality rates through the 120 months follow-up, and utilize Focus Groups from national and international study sites to evaluate patient's perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition; and long-term psychosocial impact and nutrition challenges, and to evaluate the differences in the histological/mucosal healing between Kono-S and Side-to-Side anastomoses.
Methods
Design: This will be a multi-center randomized prospective trial with 500 subjects. Patients with Crohn's ileitis or Crohn's ileocolitis requiring initial resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
Patients will be randomized into two Groups:
Group 1: Kono-S anastomosis vs. Group 2: side-to-side functional end anastomosis (control group).
The purpose of this study is to compare the postoperative recurrence of Crohn's disease between the Kono-S procedure and the side-to-side functional end anastomosis and to evaluate the surgical recurrence rate at 60 and 120 months between the groups.
In any intestine surgery, after the sick portion of the bowel is removed, the intestinal tract is restored by reconnecting the healthy ends together. The new connecting line is called anastomosis and could be created in a variety of ways by the surgeon. This study will compare two different intestinal connections called Kono-S anastomosis and the traditional side-to-side functional end anastomosis. Initial studies have demonstrated that the Kono-S anastomosis has prevented endoscopic evidence of the post-operative recurrence of Crohn's disease at greater rates than the traditional side-to-side functional end anastomosis.
Follow-up: Patients will be discharged on no prophylactic treatments, and they will be followed post-operatively at 3 to 6, 12 to 18, 60-, and 120 months with a colonoscopy to assess for endoscopic recurrence. The mucosa will be graded with the modified Rutgeerts score for postoperative recurrence. All colonoscopies are part of the standard treatment. All patients will have also standard 30 days, 3 to 6, 12 to 18, 24, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120 months follow-ups by phone call, through medical records, or during the postoperative clinic visit.
Follow-up Care: Patients with a Rutgeerts score at 3-to-6 months of:
- All participating sites follow the same endoscopic evaluation protocol at 3-6, 12-18, 60, and 120 months, using the modified Rutgeerts score for grading the endoscopic recurrence
- 0, 1, or 2a will be followed prospectively with or without introducing medical treatment at the discretion of the gastroenterologist.
- above >2a will initiate medical therapy for Crohn's disease at the discretion of the gastroenterologist.
- Should the patient's symptoms warrant, medical treatment can be initiated at any time at the discretion of the gastroenterologist. This is a standard of care
- 3 Colonoscopic images (still color photos acceptable) are taken to ensure standardized evaluation of the anastomoses and will be shown to a gastroenterologist blinded to the goal of the study for determination of the Rutgeerts score in addition to the initial evaluation by the sites endoscopists, and for additional analyses.
- post-operative endoscopic recurrence of CD using the modified Rutgeerts score at 12-18-, 60-, and 120 months between the groups. An endoscopic Rutgeerts score of 2b or higher will be considered a recurrence.
- Time to surgical recurrence between Group1 and Group2 measured in months from the index surgery
- Work Productivity and Activity Impairment (WPAI) questionnaire (a 6-item questionnaire that measures the amount of absenteeism and presenteeism due to health problems) will be administered annually for up to 120 months.
- Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (a 10-item shortened version of the original IBDQ, measuring the quality of life in four domains: bowel symptoms, emotional health, systemic systems, and social function) will be administered annually for up to 120 months.
- The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score measuring the patient perception of illness before surgery, at 24-, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120-months post-procedure.
- Harvey Bradshaw Index as a marker of clinical disease activity will be used. This will be recorded before the procedure (baseline), at 3 to 6 and 12-18 months, 24-, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120-months post-procedure.
- Other monitoring- monitor medication therapy, readmission rates, postoperative morbidity and mortality rates annually through the 120 months of follow-up between the groups
- Focus groups from national and international study sites to evaluate patients' perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition; and long-term psychosocial impact and nutrition challenges. This is a qualitative evaluation.
- surgical pathology margin evaluation will be used to assess for histologic predictors for endoscopic and clinical remission in Crohn's Disease after ileocecal resection
- The differences in the histological mucosal healing between Kono-S and Side- to Side anastomosis measured by the histological score between the groups using the modified Global Histology Activity Score (Modified) between the groups at 60 months.
- Conditions
- Crohn's Disease
- Being tested
- side-to-side functional end anastomosis, Kono-S analstomosis
- Keywords
- Crohn's recurrence
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
side-to-side functional end anastomosisOther
type of anastomosis
Kono-S analstomosisOther
antimesenteric anastomosis
| Study group | Role | What they receive |
|---|---|---|
| side-to-side functional end anastomosis | Active comparator | side-to-side functional end anastomosis creation Receives: Other: side-to-side functional end anastomosis |
| Kono-S | Active comparator | antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis Receives: Other: Kono-S analstomosis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-operative endoscopic remission of Crohn's disease between 3 and 6 months after surgery
Endoscopic remission with a modified Rutgeerts score between 3 and 6 months in order to determine if the Kono-S procedure is more likely to prevent post-operative recurrence of Crohn's disease compared with the side-to-side functional end anastomosis. Endoscopic remission is defined as a modified Rutgeerts score of 0, 1, or 2a at 3-to-6 months post-procedure colonoscopy.
Measured: 3-6 months after surgery
Number of subjects with surgical recurrence at 60 months
Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.
Measured: 60 months after surgery
Number of subjects with surgical recurrence at 120 months
Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.
Measured: 120 months after surgery
Mucosal Healing GHS
Mucosal Healing from colonoscopy biopsies using the modified Global Histology Activity Score (Modified) score between the groups. Global Histology Activity Score (GHAS) is a widely used tool that grades biopsies of the ileum and colonic segments. The score has 8 domains and includes the presence of architectural changes, degree of chronic, neutrophilic and eosinophilic inflammatory infiltration in lamina propria, presence of intraepithelial neutrophils, epithelial damage, mucosal defects, presence of granulomas, and the extent of inflammation (proportion of biopsy specimens affected). Each domain is scored independently, and the total score is the sum of all individual scores, ranging from 2 (being the lowest meaning no histological activity) to 16 (being the highest meaning high histological disease activity).
Measured: 60 months after surgery
Mucosal Healing IBD-DCA
Mucosal Healing from colonoscopy biopsies using The Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] score between the groups. The score is validated and has 3 domains: 1) Distribution of the disease; 2) Chronicity of the disease; and 3) Activity of the disease. Each domain of the IBD-DCA is scored as one of 0 (normal), 1 (mild), or 2 (moderate to severe) based on the presence of established histological findings and the domains are separately reported.
Distribution [D] 0=Normal
- < 50% of tissue affected per same biopsy site
- ≥ 50% of tissue affected per same biopsy site Chronic features [C] 0=Normal
1=Crypt distortion and/or mild lymphoplasmacytosis 2=Marked lymphoplasmacytosis and/or marked basal plasmacytosis Activity features [A] 0=Normal
- Two or more neutrophils in lamina propria in one high-power field [HPF] and/or intraepithelial neutrophils [any number]
- Crypt abscesses, erosions, ulcers
Measured: 60 months after surgery
Surgical Pathology Margins
Histological evaluation of the surgical pathology margin evaluation for presence or absence of disease
Measured: at surgery
Secondary outcomes (12)
Post-operative endoscopic remission of Crohn's disease between 12 and 18 months, at 60-, and 120 months after surgery
Endoscopic remission with a modified Rutgeerts score at 12 to 18, 60-, and 120 months in order to determine if the Kono-S procedure is more likely to prevent post-operative recurrence of Crohn's disease compared with the side-to-side functional end anastomosis. An endoscopic Rutgeerts score of 2b or higher will be considered a recurrence.
Measured: 12-18, 60, and 120 months after surgery
Work Productivity and Activity Impairment (WPAI) due to Crohn's disease
Work Productivity and Activity Impairment (WPAI) is a validated 6-item questionnaire that measures the amount of absenteeism and presenteeism due to CD during and activity impairment the 7 days prior to administration. It consists of 6 questions with the following domains: 1) employment status; 2) hours missed due to CD; 3) hours missed due to other reasons; 4) hours actually worked; 5) the degree to which CD affected productivity while working from 0 (no effect) to 10 (maximum impairment); and 6) the degree to which CD affected regular activities from 0 (no effect) to 10 maximum impairment ). All six question' domains will be reported and compared between the groups. Between the groups and within patients, changes will be evaluated. The mean score annual variability in each domain will be evaluated.
Measured: up to 120 months
Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire for Crohn's disease(10 questions)
Validated questionnaire to evaluate the quality of life in IBD patients. The short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a 10-item shortened version of the original IBDQ, which was 32 items. Measures quality of life as measured in four domains, bowel symptoms, emotional health, systemic systems, and social function. SIBDQ score ranges between 10 and 70 points. QUOL is considered to be slightly (60-70 points), moderately (45-60 points), or severely impaired (10-45 points). In our study, the cut-off for relevant impairment of QUOL < 60 points.
Measured: up to 120 months
Clinical disease activity measured by Harvey Bradshaw Index
Harvey Bradshaw Index is a marker of clinical disease activity. The following score grading system will be used to determine the clinical disease activity:
Remission < 5 Mild disease 5-7 Moderate disease 8-16 Severe disease >16
Measured: up to 120 months
Time to surgical recurrence between Group1 and Group2
Time to surgical recurrence between Group1 and Group2 measured in months from the index surgery
Measured: up to 120 months
Focus Group
Patient Focus Groups from national and international study sites to evaluate patient's perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition, long-term psychosocial impact and nutrition challenges, and caregiver perspective on surgical treatment.
Measured: up to 120 months
Medication therapy type
Medication therapy for Crohn's disease after the index surgery. We will monitor the type of medications patients receive after surgery. The following five types of medications will be recorded: Biologics, Immunosuppressants, Corticosteroids, Anti-Inflammatory, and Antibiotics.
Measured: up to 120 months
Readmission rates between Group1 and Group2
Number of readmission due to Crohn's disease after the index surgery
Measured: up to 120 months
Mortality rate
Number of patient expired after the index surgery
Measured: up to 120 months
The Brief Illness Perception Questionnaire
The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score with the nine items rated on a scale from 0 (minimum) to 10 (maximum), with higher scores indicating a more threatening perception of the illness. The total score is calculated by summing the scores of all eight items, with a possible range of 0-80. Higher scores indicate worse illness perception.
Measured: up to 120 months
Postoperative Morbidity
Postoperative morbidity is defined as any deviation from the normal postoperative recovery course occurring within 30 days after surgery, as documented in daily in-hospital checks, clinical documentation records, imaging, laboratory results, interventional notes, or surgeon assessment, and presented as a binary outcome- "Yes" or "No".
Measured: within 30 days after surgery
Postoperative Morbidity
Postoperative morbidity is defined as any deviation from the normal postoperative recovery course occurring up to 120 months after surgery, as documented in daily in-hospital checks, clinical documentation records, imaging, laboratory results, interventional notes, or surgeon assessment, and presented as a binary outcome- "Yes" or "No".
Measured: up to 120 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2017
- Study start12 Mar 2014
- Primary completion31 Jul 2030 (estimated)
- Study completion31 Dec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- More trials run by Weill Medical College of Cornell UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
- Masking
- None (open label)
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- Crohn's and Colitis Foundation, The Leona M. and Harry B. Helmsley Charitable Trust
- Responsible party
- Sponsor
- Investigators
- Fabrizio Michelassi, MD, Principal investigator, Weill Medical College of Cornell UniversityKoianka Trencheva, Dr.PH,BSN,MS, Principal investigator, Weill Medical College of Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03256240
- Sponsor's protocol ID
- 1303013645
- Status last verified
- May 2026
- First submitted
- 5 Aug 2014
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kono T, Ashida T, Ebisawa Y, Chisato N, Okamoto K, Katsuno H, Maeda K, Fujiya M, Kohgo Y, Furukawa H. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn's disease. Dis Colon Rectum. 2011 May;54(5):586-92. doi: 10.1007/DCR.0b013e318208b90f.
PubMed 21471760Kono T, Fichera A. Kono-S anastomosis for Crohn's disease: narrative - a video vignette. Colorectal Dis. 2014 Oct;16(10):833. doi: 10.1111/codi.12722. No abstract available.
PubMed 25040294
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Randomized Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis in the Prevention of Post-operative Recurrence of Crohn's Disease
- ClinicalTrials.gov ID
- NCT03256240
- Acronym / sponsor ID
- 1303013645
- Conditions
- Crohn's Disease
- Keywords
- Crohn's recurrence
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Collaborators
- Crohn's and Colitis Foundation, The Leona M. and Harry B. Helmsley Charitable Trust
- Study start
- 12 Mar 2014 (actual)
- Primary completion
- 31 Jul 2030 (estimated)
- Study completion
- 31 Dec 2036 (estimated)
- First posted
- 21 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
Detailed description
Study Aim:
- The primary aim of this study is to compare the postoperative recurrence of CD using the modified Rutgeerts score at 3-6 months between the novel Kono-S anastomosis (Group1) and side-to-side functional end anastomosis (Group2) and surgical recurrence rate at 60 and 120 months between the groups. Evaluate histologic features in surgical specimen collected at the index surgery as predictors for endoscopic, clinical, and surgical recurrence after ileocecal resection for CD. To evaluate the histological mucosal healing at 60 months between the novel Kono-S anastomosis (Group1) and side-to-side functional end anastomosis (Group2) using Global Histology Activity Score and The Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] score.
- The secondary aim is to evaluate the postoperative endoscopic recurrence of CD using the modified Rutgeerts score at 12-18, 60 and 120 months between the groups; time to surgical recurrence between Group1 and Group2 measured in months from the index surgery; yearly Crohn's disease surgical therapy impact using the Work Productivity and Activity Impairment (WPAI) questionnaire; yearly Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire; to evaluate before surgery, and yearly after the surgery up 60 months the patient perception of illness measured by The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score between the groups, to evaluate disease activity yearly using Harvey-Bradshaw Index, and monitor medication therapy, anastomotic strictures, readmission rates, and mortality rates through the 120 months follow-up, and utilize Focus Groups from national and international study sites to evaluate patient's perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition; and long-term psychosocial impact and nutrition challenges, and to evaluate the differences in the histological/mucosal healing between Kono-S and Side-to-Side anastomoses.
Methods
Design: This will be a multi-center randomized prospective trial with 500 subjects. Patients with Crohn's ileitis or Crohn's ileocolitis requiring initial resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
Patients will be randomized into two Groups:
Group 1: Kono-S anastomosis vs. Group 2: side-to-side functional end anastomosis (control group).
The purpose of this study is to compare the postoperative recurrence of Crohn's disease between the Kono-S procedure and the side-to-side functional end anastomosis and to evaluate the surgical recurrence rate at 60 and 120 months between the groups.
In any intestine surgery, after the sick portion of the bowel is removed, the intestinal tract is restored by reconnecting the healthy ends together. The new connecting line is called anastomosis and could be created in a variety of ways by the surgeon. This study will compare two different intestinal connections called Kono-S anastomosis and the traditional side-to-side functional end anastomosis. Initial studies have demonstrated that the Kono-S anastomosis has prevented endoscopic evidence of the post-operative recurrence of Crohn's disease at greater rates than the traditional side-to-side functional end anastomosis.
Follow-up: Patients will be discharged on no prophylactic treatments, and they will be followed post-operatively at 3 to 6, 12 to 18, 60-, and 120 months with a colonoscopy to assess for endoscopic recurrence. The mucosa will be graded with the modified Rutgeerts score for postoperative recurrence. All colonoscopies are part of the standard treatment. All patients will have also standard 30 days, 3 to 6, 12 to 18, 24, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120 months follow-ups by phone call, through medical records, or during the postoperative clinic visit.
Follow-up Care: Patients with a Rutgeerts score at 3-to-6 months of:
- All participating sites follow the same endoscopic evaluation protocol at 3-6, 12-18, 60, and 120 months, using the modified Rutgeerts score for grading the endoscopic recurrence
- 0, 1, or 2a will be followed prospectively with or without introducing medical treatment at the discretion of the gastroenterologist.
- above >2a will initiate medical therapy for Crohn's disease at the discretion of the gastroenterologist.
- Should the patient's symptoms warrant, medical treatment can be initiated at any time at the discretion of the gastroenterologist. This is a standard of care
- 3 Colonoscopic images (still color photos acceptable) are taken to ensure standardized evaluation of the anastomoses and will be shown to a gastroenterologist blinded to the goal of the study for determination of the Rutgeerts score in addition to the initial evaluation by the sites endoscopists, and for additional analyses.
- post-operative endoscopic recurrence of CD using the modified Rutgeerts score at 12-18-, 60-, and 120 months between the groups. An endoscopic Rutgeerts score of 2b or higher will be considered a recurrence.
- Time to surgical recurrence between Group1 and Group2 measured in months from the index surgery
- Work Productivity and Activity Impairment (WPAI) questionnaire (a 6-item questionnaire that measures the amount of absenteeism and presenteeism due to health problems) will be administered annually for up to 120 months.
- Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (a 10-item shortened version of the original IBDQ, measuring the quality of life in four domains: bowel symptoms, emotional health, systemic systems, and social function) will be administered annually for up to 120 months.
- The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score measuring the patient perception of illness before surgery, at 24-, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120-months post-procedure.
- Harvey Bradshaw Index as a marker of clinical disease activity will be used. This will be recorded before the procedure (baseline), at 3 to 6 and 12-18 months, 24-, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120-months post-procedure.
- Other monitoring- monitor medication therapy, readmission rates, postoperative morbidity and mortality rates annually through the 120 months of follow-up between the groups
- Focus groups from national and international study sites to evaluate patients' perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition; and long-term psychosocial impact and nutrition challenges. This is a qualitative evaluation.
- surgical pathology margin evaluation will be used to assess for histologic predictors for endoscopic and clinical remission in Crohn's Disease after ileocecal resection
- The differences in the histological mucosal healing between Kono-S and Side- to Side anastomosis measured by the histological score between the groups using the modified Global Histology Activity Score (Modified) between the groups at 60 months.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
| Arm | Type | Receives |
|---|---|---|
| side-to-side functional end anastomosis | Active comparator | Other: side-to-side functional end anastomosisside-to-side functional end anastomosis creation |
| Kono-S | Active comparator | Other: Kono-S analstomosisantimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients with Crohn's ileitis or ileocolitis requiring initial surgical resection.
- Age of 18 years and older, male and female
- All Phenotypes of Crohn's diisease will be included: nonpenetrating (B1), stricturing (B2), and penetrating (fistulating) (B3), according to the Vienna classification
- The patients can be on any medications coming into surgery, including prior anti- tumor necrosis factor(TNF) therapy.
Key exclusion criteria (7 listed)
- Patients under 18 years of age
- Patients with recurrent Crohn's
- Pregnant patients
- Patients with more than one non-contiguous site of active disease, thus requiring multiple resections or additional bowel sparing procedures at the time of surgery.
- Patients with Crohn's disease extending to the cecum and ascending colon
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| side-to-side functional end anastomosistype of anastomosis | Other | side-to-side functional end anastomosis |
| Kono-S analstomosisantimesenteric anastomosis | Other | Kono-S |
Primary outcome
Post-operative endoscopic remission of Crohn's disease between 3 and 6 months after surgery
Time frame: 3-6 months after surgery
Endoscopic remission with a modified Rutgeerts score between 3 and 6 months in order to determine if the Kono-S procedure is more likely to prevent post-operative recurrence of Crohn's disease compared with the side-to-side functional end anastomosis. Endoscopic remission is defined as a modified Rutgeerts score of 0, 1, or 2a at 3-to-6 months post-procedure colonoscopy.
Number of subjects with surgical recurrence at 60 months
Time frame: 60 months after surgery
Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.
Number of subjects with surgical recurrence at 120 months
Time frame: 120 months after surgery
Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.
Mucosal Healing GHS
Time frame: 60 months after surgery
Mucosal Healing from colonoscopy biopsies using the modified Global Histology Activity Score (Modified) score between the groups. Global Histology Activity Score (GHAS) is a widely used tool that grades biopsies of the ileum and colonic segments. The score has 8 domains and includes the presence of architectural changes, degree of chronic, neutrophilic and eosinophilic inflammatory infiltration in lamina propria, presence of intraepithelial neutrophils, epithelial damage, mucosal defects, presence of granulomas, and the extent of inflammation (proportion of biopsy specimens affected). Each domain is scored independently, and the total score is the sum of all individual scores, ranging from 2 (being the lowest meaning no histological activity) to 16 (being the highest meaning high histological disease activity).
Mucosal Healing IBD-DCA
Time frame: 60 months after surgery
Mucosal Healing from colonoscopy biopsies using The Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] score between the groups. The score is validated and has 3 domains: 1) Distribution of the disease; 2) Chronicity of the disease; and 3) Activity of the disease. Each domain of the IBD-DCA is scored as one of 0 (normal), 1 (mild), or 2 (moderate to severe) based on the presence of established histological findings and the domains are separately reported. Distribution [D] 0=Normal 1. < 50% of tissue affected per same biopsy site 2. ≥ 50% of tissue affected per same biopsy site Chronic features [C] 0=Normal 1=Crypt distortion and/or mild lymphoplasmacytosis 2=Marked lymphoplasmacytosis and/or marked basal plasmacytosis Activity features [A] 0=Normal 1. Two or more neutrophils in lamina propria in one high-power field [HPF] and/or intraepithelial neutrophils [any number] 2. Crypt abscesses, erosions, ulcers
Surgical Pathology Margins
Time frame: at surgery
Histological evaluation of the surgical pathology margin evaluation for presence or absence of disease
12 secondary outcomes
Post-operative endoscopic remission of Crohn's disease between 12 and 18 months, at 60-, and 120 months after surgery
Time frame: 12-18, 60, and 120 months after surgery
Work Productivity and Activity Impairment (WPAI) due to Crohn's disease
Time frame: up to 120 months
Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire for Crohn's disease(10 questions)
Time frame: up to 120 months
Clinical disease activity measured by Harvey Bradshaw Index
Time frame: up to 120 months
Time to surgical recurrence between Group1 and Group2
Time frame: up to 120 months
Focus Group
Time frame: up to 120 months
Medication therapy type
Time frame: up to 120 months
Readmission rates between Group1 and Group2
Time frame: up to 120 months
Mortality rate
Time frame: up to 120 months
The Brief Illness Perception Questionnaire
Time frame: up to 120 months
Postoperative Morbidity
Time frame: within 30 days after surgery
Postoperative Morbidity
Time frame: up to 120 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Background: PubMed 21471760Kono T, Ashida T, Ebisawa Y, Chisato N, Okamoto K, Katsuno H, Maeda K, Fujiya M, Kohgo Y, Furukawa H. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn's disease. Dis Colon Rectum. 2011 May;54(5):586-92. doi: 10.1007/DCR.0b013e318208b90f.
- Background: PubMed 25040294Kono T, Fichera A. Kono-S anastomosis for Crohn's disease: narrative - a video vignette. Colorectal Dis. 2014 Oct;16(10):833. doi: 10.1111/codi.12722. No abstract available.
Related trials for Crohn's Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Fabrizio Michelassi, MD principal investigator
Weill Medical College of Cornell University
Koianka Trencheva, Dr.PH,BSN,MS principal investigator
Weill Medical College of Cornell University
15 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing side-to-side functional end anastomosis and Kono-S analstomosis in people with Crohn's Disease, run by Weill Medical College of Cornell University at 15 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in United States, Germany, Italy, Belgium, Finland and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Koianka Trencheva, Dr.PH,BSN,MS (646-962-2342, kivanova@med.cornell.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-operative endoscopic remission of Crohn's disease between 3 and 6 months after surgery (time frame: 3-6 months after surgery). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03256240, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.